HFHS approved uses for Intravenous Immune Globulin (IVIG)
Disease
Recommendation
CIDP where plasmapheresis, corticosteroids, or other immune-modulating agents are not clinically appropriate
0.4 g/kg/day x 5 days, or 1 g/kg x 2 days
Guillain-Barre’ Syndrome where plasmapharesis is not clinically appropriate
0.4 g/kg/day x 5 days
HCT recipients, patient with multiple myeloma or CLL with recurrent (>/=3 /year) bacterial, sino-pulmonary infections with documented IgG<400mg/dL.
0.4 g/kg Q 3-4 weeks
Give monthly IVIG to keep IgG > 400-500 mg/dL.
Idiopathic Thrombocytopenic Purpura with Active Bleeding
0.4 g/kg/day x 5 days, or 1 g/kg x 1-2 days
Myasthenia gravis Crisis where plasmapheresis is not clinically appropriate
0.4 g/kg/day for 5 days, or 1 g/kg x 2 days
Multifocal Motor Neuropathy (MMN)
0.4 g/kg x 5 days, or 1 g/kg x 2 days
PANDAS [or post-infectious encephalitis or disseminated encephalomyelitis] in current & established HFHS pediatric patients
Initial dose: 2 g/kg over 5 days, then 1-2 g/kg every month x 3-6 months, and then once every 3-6 months thereafter. Dosing and frequency after initial dose is lower and individualized
Primary Immunodeficiency Diseases with documented IgG<400mg/dL and documented severe lung disease(s)
0.4-0.6 g/kg Q 21-28 days [titrated to response]
Solid Organ Transplant:
Antibody mediated rejection – All organs, biopsy positive and diagnosed early in the rejection process
HFHS approved uses for Intravenous Immune Globulin (IVIG)
Disease
0.4 g/kg Q 3-4 weeks
Give monthly IVIG to keep IgG > 400-500 mg/dL.Solid Organ Transplant:
Antibody mediated rejection – All organs, biopsy positive and diagnosed early in the rejection process